Stock & Company Details
Clearmind Medicine Inc $CMND
Price:
46,691,331
1M
$3.3M
52 Week High:
$66.15
10 Day Average Volume:
42,760,466
0.00
50 Day Moving Average:
$156.49
52 Week Low:
$43.74
30 Day Average Volume:
49,506,373
$4.94
2021-02-05
0.95
30 Day Change:
13%
3 Month Change:
-0.32%
Finance
CMND technical indicators
Latest Clearmind Medicine Inc (CMND) technical indicators as of 2026-07-01: RSI, MACD, moving averages (SMA & EMA), Bollinger Bands, Stochastic, ADX, ATR, CCI, OBV and ROC.
RSI 14:
44.52 5.7%
MACD:
0.06 39.0%
SMA 50:
$1.90 1.2%
SMA 200:
$1.38 0.5%
EMA 20:
$2.64 1.3%
Bollinger Bands:
3.95 / 2.04
Stochastic:
14.77 56.4%
ADX 14:
36.37 5.5%
ATR 14:
0.35 4.4%
CCI 20:
-129.03 18.0%
OBV:
488.70M 0.0%
ROC 12:
-31.14% 8.8%
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Finance Bot
Ask your questions
Start by typing a question below.
